Nelfinavir at six months. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Nelfinavir at six months. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

PI Perspect. 1997 Mar;(No 21):11-2. Unique Identifier : AIDSLINE AIDS/97702498

Abstract: Nelfinavir, the newest protease inhibitor to be approved by the Food and Drug Administration (FDA), showed promising preliminary data when it was combined with AZT and 3TC in treatment-naive populations. Agouron Pharmaceuticals started pediatric trials early in the drug's development, showing that a 20-30 mg/kg dose taken 3 times daily produced roughly the same benefits as 500 to 750 mg in adults. When, where, and how to use nelfinavir in the overall mix of antiviral therapies is still in question. The resistance pattern seems different from the other protease inhibitors and might make it possible to switch to ritonavir or indinavir successfully even after acquiring resistance to nelfinavir. Also, nelfinavir is well-tolerated, has moderate side effects, and can be taken with food. Unfortunately, it may not be as potent as indinavir or ritonavir at currently recommended doses.

Keywords: Anti-HIV Agents/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE CD4 Lymphocyte Count Child Clinical Trials Drug Therapy, Combination HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE Human Isoquinolines/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE Lamivudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Sulfonic Acids/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE Viral Load Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE NEWSLETTER ARTICLE
970830
M9781251

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .